TLR7 and neoplasm: Another notable study by Turco et al. [376] investigated β-CYD nanoparticles (CDNP) encapsulating the Toll-like receptor 7 and 8 (TLR7/8) agonist R848, targeting immunosuppressive tumor-associated myeloid cells (TAMs) in GB.